WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) and the Canadian medical technology association MEDEC announce that MEDEC recently approved a number of guidances and tools designed to promote ethical interactions between medical device and diagnostics companies and third-party distributors.
Each July 4th we celebrate our independence as a nation and as a free people. The freedom and the opportunity to elect our leaders and representatives is as important today as it was in 1776.
Castellani Statement on Prescription Drug Costs
Washington, D.C. (May 29, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani today released the following statement on the cost and value of medicines:Continue reading
Second White Paper Reviews Proposals Made in the President’s Council of Advisors on Science and Technology 2012 Report on Propelling Innovation – Health Subcommittee Schedules Hearing on PCAST for May 20 Continue reading
The Council of State Bioscience Associations (CSBA) is a confederation of state-based, non-profit trade organizations each governed by its own board of directors. The common mission of the members of the CSBA is to promote public understanding, and to advocate for public policies that support the responsible development of the bioscience industry. These groups are recognized by BIO as affiliate organizations in their respective states. AZBio is Arizona’s Authorized BIO affiliate and a proud member of CSBA.Continue reading
A path to 21st century cures being mapped by the Senate Energy and Commerce CommitteeContinue reading
PHOENIX, 5/1/14 – Arizona Governor Jan Brewer signed House Bill 2078 into law Wednesday, making Arizona the 32nd state in the United States to have cost-parity for oral anticancer drugs. Beginning January 1, 2016, HB2078, sponsored by Representative Heather Carter (LD15), requires health insurance companies with plans that cover intravenous (IV) anticancer treatments and oral anticancer treatments to not discriminate against oral treatments by way of higher co-payments, deductibles or coinsurance.Continue reading
While well intentioned, State “Right to Try” bills are fraught with false hope and dangerous side effects.Continue reading
Washington, DC (March 5, 2014) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to President Obama’s FY 2015 budget proposal:Continue reading